Sarepta shares tumble after report of patient death in early-stage trial

Published 18/07/2025, 11:38
© Reuters.

Investing.com -- Sarepta Therapeutics shares plunged premarket on Friday after the company disclosed another patient death linked to its gene therapy programs, this time during an early-stage trial for limb-girdle muscular dystrophy, according to Bloomberg.

The report stated that a Sarepta (NASDAQ:SRPT) spokesperson told Bloomberg that a patient died last month from acute liver failure after receiving an experimental treatment. 

Regulators and trial investigators were informed “in an appropriate and timely manner,” the spokesperson added in a statement cited by Bloomberg.

“While we do everything possible to ensure patient safety, there is inherent risk in clinical trials, and we are grateful to the courageous patients and families who participate,” the spokesperson said.

Shares of Sarepta dropped as much as 22% in premarket trading and are down about 85% in the past 12 months through Thursday’s close.

Bloomberg noted that the latest fatality follows two earlier deaths involving teenage boys who died of acute liver failure while being treated with Elevidys, Sarepta’s gene therapy approved for Duchenne muscular dystrophy. 

On Wednesday, Sarepta said it would add a liver failure warning to Elevidys’ label at the request of the U.S. Food and Drug Administration.

On the same day, Sarepta announced plans to cut more than one-third of its workforce and pause several pipeline programs, which it expects will contribute to an expected $400 million in annual cost savings.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.